Actionable driver oncogene mutations were excluded from neoadjuvant chemoimmunotherapy of non-small cell lung cancer.

These known actionable driver oncogene mutations were excluded from neoadjuvant chemoimmunotherapy of non-small cell lung cancer in a retrospective cohort study, as they had corresponding target treatments.在一项针对非小细胞肺癌（non-small cell lung cancer）新辅助化疗免疫治疗（neoadjuvant chemoimmunotherapy）的回顾性队列研究（retrospective cohort study）中，本研究排除了携带此类已知可靶向驱动癌基因突变（actionable driver oncogene mutation）的受试者，因该类突变存在对应的靶向治疗方案。